The Power of Synergism: A Novel Drug Combination for Improved Therapy of Glioblastoma

One of the biggest obstacles in treating glioblastoma multiforme (GBM) is the plasticity and adaptability of GBM cells, which renders monotherapy ineffective. Novel drug combinations that target multiple pathways are required to overcome this challenge. In the current study, the PI3K/AKT/mTOR pathway is identified as a crucial component in GBM cell survival using the KEGG database and literature search. Hence, it is hypothesized that a potential synergistic therapy can be achieved by targeting different stages of this pathway by combining disulfiram (DSF) and 7-ethyl-10-hydroxycamptothecin (SN-38). The efficacy of this drug combination is evaluated using 2D and 3D in vitro assays, which exhibited a significant synergism with 5 x 104 times lower IC50 than that of temozolomide (TMZ), the gold-standard drug. The combination treatment increases intracellular ROS (reactive oxygen species) production, and ROS inhibition by using N-Acetyl Cysteine (NAC) reduced the cytotoxicity substantially, indicating that ROS played a crucial role in the synergistic cytotoxicity. The combination treatment inhibited GBM cell proliferation, migration, and stem cell marker expression. Mechanistically, the DSF+SN-38 combination is found to increase p53 expression, inhibit PI3K signaling, and activate caspase 9. Altogether, this study demonstrates that the DSF+SN-38 combination can present a promising therapeutic strategy for treating GBM. The study identified the PI3K/AKT/mTOR pathway as crucial for glioblastoma multiforme (GBM) progression, leading to a hypothesis of combining disulfiram (DSF) and 7-ethyl-10-hydroxycamptothecin (SN-38) for effective therapy. This combination showed significant synergy. It increased ROS production and inhibited GBM cell functions. Mechanistically, DSF+SN-38 activated caspase 9, inhibited PI3K, and increased p53 expression, suggesting a promising GBM treatment strategy. image